Category Archives: Press Releases

First participant imaged in Phase II SAR-Bombesin prostate cancer trial in the US

Sydney, Australia 6 October 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce it has successfully imaged its first participant in the US-based diagnostic 64Cu SAR-Bombesin trial (SABRE NCT05407311)1 for patients with PSMA-negative…

First participants imaged in SAR-Bombesin prostate cancer trial in Australia

Sydney, Australia 14 September 2022 Highlights First participants were recruited and imaged in the diagnostic investigator-initiated trial (IIT) led by Prof Louise Emmett at St Vincent’s Hospital Sydney with one of Clarity’s core products, SAR-Bombesin The Phase II IIT builds on the data generated in PSMA-negative prostate cancer patients imaged at St Vincent’s Hospital under…

Radiopharmaceuticals Expert Joins Clarity as Chief Scientific Officer

Sydney, Australia 13 September 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the appointment of Dr Jeffrey Norenberg as Chief Scientific Officer (CSO), effective immediately. Dr Norenberg has more…

Clarity strengthens protection of the SAR-bisPSMA product with granting of China patent

Sydney, Australia 12 September 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the patent application covering Clarity’s optimised Prostate Specific Membrane Antigen (PSMA) targeting agent, SAR-bisPSMA, has been Granted in China.…

Recruitment opens for Phase II trial in prostate cancer with Cu-64 SAR-Bombesin in the US

Sydney, Australia 5 September 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the US-based diagnostic 64Cu SAR-Bombesin trial (SABRE NCT05407311)1 for patients with PSMA-negative prostate cancer is open for recruitment. SABRE (Copper-64…

Clarity advances to cohort 3 of the CL04 trial of SARTATE™ in paediatric neuroblastoma

Sydney, Australia 23 August 2022 Highlights Cohort 2 completed in participants with neuroblastoma who received therapy with 67Cu SARTATE™ at a dose of 175MBq/kg body weight No Dose Limiting Toxicities (DLTs) have been reported in cohort 1 and cohort 2 Safety Review Committee (SRC) has recommended the trial continues with the dose escalation phase as…

Imaging trial with SAR-Bombesin in prostate cancer opens for recruitment in Australia

Sydney, Australia 22 August 2022 Highlights Diagnostic investigator-initiated trial (IIT) with one of Clarity’ core products, SAR-Bombesin, commenced at St Vincent’s Hospital Sydney, led by Prof Louise Emmett. The Phase II IIT builds on the data generated in PSMA-negative prostate cancer patients at St Vincent’s Hospital imaged under the Therapeutic Goods Administration (TGA) Special Access…

Clarity expands manufacturing capabilities for its Cu-64 SAR-bisPSMA clinical programs

Sydney, Australia 11 August 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, has signed a supply agreement with 3D Imaging LLC. (3DI), a Contract Development and Manufacturing Organisation (CDMO), covering Clarity’s diagnostic 64Cu SAR-bisPSMA product. The new agreement, effective on August 11th, 2022,…

Clarity and Evergreen expand Targeted Copper Theranostics manufacturing

Sydney, Australia 9 August 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, and Evergreen Theragnostics, Inc. (“Evergreen”), a radiopharmaceutical contract development and manufacturing organisation, are pleased to announce that the companies have expanded their Targeted Copper Theranostics (TCTs) manufacturing agreement to include next-generation…

Recruitment complete for Clarity’s PROPELLER prostate cancer diagnostic trial

Sydney, Australia 20 July 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce the completion of recruitment for the Phase I PROPELLER diagnostic trial evaluating its 64Cu-SAR-bisPSMA product candidate in patients with untreated, confirmed prostate cancer, scheduled for radical prostatectomy.…